Home/Pipeline/Ultra-rapid insulin

Ultra-rapid insulin

Type 1 Diabetes

ClinicalActive

Key Facts

Indication

Type 1 Diabetes

Phase

Clinical

Status

Active

Company

Arecor

About Arecor

Arecor is a UK-based biopharma company utilizing its Arestat® formulation technology to create superior drug products in diabetes and cardiometabolic diseases. The company has a dual strategy: advancing its own clinical-stage pipeline of next-generation insulins and developing an oral peptide delivery platform, while also generating revenue through technology licensing partnerships. With one partnered product already on the market generating royalties and a robust intellectual property portfolio, Arecor aims to improve patient outcomes through enhanced drug delivery.

View full company profile

Therapeutic Areas

Diabetes Cardiometabolic Diseases Obesity

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
eRapa	Biodexa Pharmaceuticals	Preclinical	Research
ImmCelz™	Creative Medical Technology Holdings	Clinical Trial	Active
Adimune (ADi-001/002)	Aditxt	Preclinical / Early Clinical	Active
MSC‑Diabetes	Advancells	Phase 1	Active
BioChaperone® Lispro (THDB0206)	Adocia	Phase 3	Active
AdoShell® Islet Cell Therapy	Adocia	Preclinical	Platform Development
Pediatric Indications (<2 years)	Tandem Diabetes	Research	Exploratory
Icovamenib (BMF-219)	Biomea Fusion	Phase 2	Completed Follow-up, Data Pending
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research
Sotagliflozin	Lexicon Pharmaceuticals	Phase 3	Regulatory Path Uncertain
Stem Cell-Derived Beta Cells	BioTalentum	Pre-clinical	Active
NICHE	Continuity Biosciences	Pre-clinical	Active